Lung cancer survival rates
Pro Research Analysisby 
Searched over 200M research papers
Lung Cancer Survival Rates by Stage and Histological Type
Lung cancer survival rates vary greatly depending on the stage at diagnosis and the type of lung cancer. For non-small cell lung cancer (NSCLC), which accounts for the majority of cases, 5-year survival rates are highest at early stages and drop sharply as the disease advances. In South Korea, the 5-year relative survival rates for NSCLC are 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV. For small cell lung cancer (SCLC), the rates are much lower: 16% for limited disease and just 4% for extensive disease. Genetic factors, such as the presence of EGFR mutations or ALK translocations, can improve survival in advanced NSCLC, with some subgroups reaching up to 38% 5-year survival in stage IV disease .
Similar trends are observed in China, where the 5-year overall survival rates for lung cancer are 76.9% at stage I, 56.1% at stage II, 32.6% at stage III, and 21.4% at stage IV. Survival also differs by histological type: adenocarcinoma patients have a 5-year survival rate of 43.3%, squamous cell carcinoma 36.9%, and small cell carcinoma 27.9% . Early detection is crucial, as patients diagnosed at stage I can have 5-year survival rates as high as 70–82%, while those with metastatic (stage IV) disease often have rates below 20% 123.
Global and Regional Trends in Lung Cancer Survival
Survival rates for lung cancer have improved over recent decades in many countries, but overall rates remain low. In Hungary, the 5-year overall survival rate for lung cancer is 17.9%, with better outcomes for women and younger patients. The highest survival is seen in patients aged 20–49 (31.3%) and those with adenocarcinoma (20.5%). There has been a modest improvement in survival over recent years, particularly among younger women .
In Taiwan, significant improvements in survival have been observed, with the predicted 5-year survival rate for 2020 reaching 38.7%, up from 23.8% in 2013. These gains are attributed to advances in screening, diagnostics, and treatment . In the Nordic countries, 5-year survival rates for lung cancer in 2016–2020 ranged from 26.6% for men to 33.2% for women, with marked improvements since 2000 due to better access to curative treatments and early detection .
However, in resource-limited regions such as northeastern Iran, survival remains extremely poor, with a 5-year survival rate of just 1.56% and a median survival of only four months after diagnosis. This highlights the importance of access to diagnostic and treatment services in improving outcomes .
Impact of Early Detection and Treatment on Survival
Early detection through screening and prompt treatment significantly improves lung cancer survival. Studies show that patients diagnosed through regular screening (such as six-monthly chest radiographs) have higher 5-year survival rates (23%) compared to those diagnosed without screening (6%). Surgical resection of early-stage tumors can result in 5-year survival rates of up to 70–82% 137.
Without treatment, lung cancer prognosis is extremely poor. For patients with NSCLC who receive no anticancer therapy, the average survival is about 7 months, with a 5-year mortality rate of 97% .
Long-Term Trends and Future Prospects
Over the past four decades, the 5-year relative survival rate for lung cancer has increased but remains below 21% in many regions. Improvements are linked to advances in surgery, chemotherapy, radiotherapy, and targeted therapies, as well as public health measures such as anti-smoking campaigns and early detection programs 910. Ongoing progress in medical technology and health policy is expected to further improve survival rates in the future 510.
Conclusion
Lung cancer survival rates are highly dependent on stage at diagnosis, histological type, and access to modern treatments. Early detection and advances in therapy have led to improved outcomes in many countries, but survival remains low, especially in advanced stages and resource-limited settings. Continued efforts in early diagnosis, targeted therapies, and public health interventions are essential to further improve lung cancer survival worldwide 12345678+2 MORE.
Sources and full results
Most relevant research papers on this topic